Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

20 Aug 2014

Abstract excerpt

This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Research on Leishmaniasis Studies
Share to Synthesis and Biological Evaluation
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25317712
DOI: 10.1590/0074-0276140156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversityPMID 25317712Read ↗

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.Semantic proximity Read ↗

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent <i>Trypanosoma cruzi</i> strains as a resource for Chagas disease researchSemantic proximity Read ↗

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research.Semantic proximity Read ↗

Fifteen Years after the Definition of <em>Trypanosoma cruzi </em>DTUs: What Have We Learned?Semantic proximity Read ↗

<em>Trypanosoma cruzi</em> STIB980: A TcI Strain for Drug Discovery and Reverse GeneticsSemantic proximity Read ↗

Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound SelectionSemantic proximity Read ↗

Trypanosoma cruzi Arequipa: a tool for Chagas disease drug discoverySemantic proximity Read ↗

Phenotypic screening approaches for Chagas disease drug discovery.Semantic proximity Read ↗

Fifteen Years after the Definition of Trypanosoma cruzi DTUs: What Have We Learned?Semantic proximity Read ↗

TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine modelSemantic proximity Read ↗

Trypanosoma cruzi DTU diversity, benznidazole response, and clinical manifestations of Chagas disease: a seventeen-year systematic review and meta-analysis.Semantic proximity Read ↗

Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human–host interactionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.